(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 6.08% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Thermo Fisher Scientific's revenue in 2026 is $45,197,000,000.On average, 29 Wall Street analysts forecast TMO's revenue for 2026 to be $17,938,539,737,015, with the lowest TMO revenue forecast at $17,301,208,924,540, and the highest TMO revenue forecast at $18,740,498,858,485. On average, 29 Wall Street analysts forecast TMO's revenue for 2027 to be $18,926,681,212,450, with the lowest TMO revenue forecast at $18,206,107,191,815, and the highest TMO revenue forecast at $19,837,153,801,700.
In 2028, TMO is forecast to generate $20,087,626,669,110 in revenue, with the lowest revenue forecast at $19,170,093,272,025 and the highest revenue forecast at $21,400,565,304,955.